These findings indicate that TRPV4 deletion alleviates the effects of isoproterenol infusion on cardiac hypertrophy and especially on cardiac fibrosis, thereby providing protection against the development of adverse cardiac remodeling and inducible arrhythmias. The gene discussed is TRPV4; the disease is cardiac hypertrophy.